Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of Omalizumab Withdrawal After a 3 Year Duration Treatment in Well Controlled Severe Allergic Asthma : a Multicentric Randomized Controlled Trial

NCT04763447 is registered in ClinicalTrials.gov with Assistance Publique - Hôpitaux de Paris as lead sponsor.

NCT NCT04763447
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04763447 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of Omalizumab Withdrawal After a 3 Year Duration Treatment in Well Controlled Severe Allergic Asthma : a Multicentric Randomized Controlled Trial
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Phase
Phase 4
Overall status
Recruiting
Start date
May 20, 2021
Completion date
May 20, 2027
Enrollment
234 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

asthma